STAT+: Viking Therapeutics releases early but promising weight loss data on new GLP-1 drug
Viking Therapeutics, a small biotechnology company, said its experimental medicine led patients to lose as much as 6% more body weight than those on placebo in just six days.
Viking Therapeutics, a small biotechnology company, said Tuesday that its experimental medicine led patients to lose as much as 6% more body weight than those on placebo in just 28 days.
The results are from a small, early Phase 1 study, and the drug will require much more research in studies of thousands of patients in order to establish its efficacy and safety. But the results, made public in a press release, were so promising that they led investors to bid the company’s stock up 45% in early morning trading.
What's Your Reaction?
